Dr. Charles Baker -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Charles Baker, a Allergy & Immunology physician based in Lowell, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Charles Baker has received $19,702.74 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Charles Baker has received a total of $19,702.74 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $19,702.74 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Charles Baker's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Speaking & Education$19,702.74Promotional speaking, CME events, and educational presentations

The largest payment category for Dr. Charles Baker is Speaking & Education, accounting for 100% ($19,702.74) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Charles Baker. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Regeneron Pharmaceuticals$19,702.741

Dr. Charles Baker has a financial relationship with Regeneron Pharmaceuticals, receiving $19,702.74 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Charles Baker's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Charles Baker has received $19.7K across 1 pharmaceutical payments as a Allergy & Immunology physician in Lowell, MA. Top paying companies include Regeneron Pharmaceuticals ($19.7K). The physician received a single, substantial payment of $19,703 in 2024. This payment originated entirely from Regeneron Pharmaceuticals. The payment was categorized as 'speaking' fees, indicating a potential educational or advisory role.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Charles Baker is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may want to ask their allergist about any relationships they have with pharmaceutical companies, especially if they are prescribed medications from those companies. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Charles Baker Compares to Other Allergy & Immunology Physicians

For an Allergy & Immunology specialist, receiving a single speaking fee from a pharmaceutical company is not uncommon, though the amount is notable.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Charles Baker in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Regeneron Pharmaceuticals$19,702.74speakingN/A2024-10-04Not Assessed

Frequently Asked Questions About Dr. Charles Baker's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Charles Baker received?

Charles Baker has received a total of $19.7K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Charles Baker taking too much pharma money?

Charles Baker has received $19.7K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Allergy & Immunology), the types of payments, and how they compare to peers. The largest payment category is speaking ($19.7K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Charles Baker?

The top pharmaceutical companies paying Charles Baker are: Regeneron Pharmaceuticals ($19.7K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Charles Baker receive?

Charles Baker's payments by type: speaking: $19.7K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Charles Baker's payments compare to other Allergy & Immunology doctors?

To compare, look at the total amount ($19.7K), number of payments (1), and the types of payments received. Allergy & Immunology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Charles Baker's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1441984304). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Charles Baker's pharma payment profile?

The physician's payment profile is highly concentrated, with 100% of the total amount coming from a single company. Charles Baker has received $19.7K in total pharma payments.

How does Charles Baker compare to peers in Allergy & Immunology?

For an Allergy & Immunology specialist, receiving a single speaking fee from a pharmaceutical company is not uncommon, though the amount is notable.

Are Charles Baker's pharma relationships typical for Allergy & Immunology?

The single payment represents a significant amount, suggesting a specific engagement or role.

What should patients of Charles Baker know about these payments?

Patients may want to ask their allergist about any relationships they have with pharmaceutical companies, especially if they are prescribed medications from those companies.

What patterns are visible in Charles Baker's payment history?

The data only reflects one payment, making it difficult to establish a broader trend or pattern.

Understanding This Doctor Payment Report

This transparency report for Dr. Charles Baker is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Charles Baker's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Charles Baker and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.